Stay updated on Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Sign up to get notified when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.

Latest updates to the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page
- Check7 days agoChange DetectedThe page shows Revision: v3.3.4, replacing the previous v3.3.3. No study details, eligibility criteria, or other core information were altered.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page adds a footer revision note 'Revision: v3.3.3'. The 'HHS Vulnerability Disclosure' link and the previous revision note 'Revision: v3.3.2' were removed.SummaryDifference0.1%

- Check57 days agoChange Detected- Results Submitted added to the study record, and the revision updated to v3.3.2, replacing No Results Posted and v3.2.0.SummaryDifference0.1%

- Check65 days agoChange DetectedThe notification about government funding and operating status was removed from the page; this does not affect the study details, eligibility criteria, endpoints, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check86 days agoChange DetectedNo significant changes were detected on the page; the content and layout remain as before. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check107 days agoChange DetectedUpdate: new operating-status notice and v3.2.0 release; removes the old v3.1.0 tag.SummaryDifference3%

Stay in the know with updates to Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.